ADReCS

Pharmaceutical Information

Drug Name	Capecitabine
Drug ID	BADD_D00349
Description	Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage	For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status	approved; investigational
ATC Code	L01BC06
DrugBank ID	DB01101
KEGG ID	D01223
MeSH ID	D000069287
PubChem ID	60953
TTD Drug ID	D00HCQ
NDC Product Code	55111-893; 82920-001; 72205-007; 72485-205; 62331-043; 16714-467; 51407-640; 55111-496; 55111-497; 61269-475; 65162-844; 15308-0714; 54893-0002; 59651-205; 64980-277; 70756-815; 68001-487; 69097-949; 72205-006; 63482-099; 72969-094; 16729-072; 59923-721; 61269-470; 0054-0271; 69539-019; 0093-7473; 64980-276; 0054-0272; 69097-948; 72606-554; 53104-7618; 55512-0015; 0004-1100; 51407-639; 67877-459; 68001-488; 69539-020; 35369-0010; 16729-073; 51407-096; 62756-238; 62756-239; 65162-843; 67877-458; 59651-204; 72485-204; 72606-555; 49452-1713; 68554-0033; 0004-1101; 0093-7474; 51407-095; 60687-149; 0378-2511; 70756-816; 53183-4009; 54245-7014; 65129-1241; 81955-0001; 16714-468; 59923-722
UNII	6804DJ8Z9U
Synonyms	Capecitabine \| N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine \| Xeloda

Chemical Information

Molecular Formula	C15H22FN3O6
CAS Registry Number	154361-50-9
SMILES	CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Infusion site pain	12.07.05.002; 08.02.05.014	-	-	Not Available
IIIrd nerve disorder	17.04.02.005; 06.05.02.015	0.000112%
Cerebral haematoma	17.08.01.014; 24.07.04.006	0.000224%		Not Available
Dacryostenosis acquired	06.06.04.003	0.000168%		Not Available
Skin burning sensation	23.03.03.021; 17.02.06.009	0.000851%		Not Available
Mucosal discolouration	08.01.06.008	0.000112%		Not Available
Hepatic cancer metastatic	16.07.02.002; 09.04.02.006	0.000112%		Not Available
Necrotising enterocolitis neonatal	18.04.11.002; 07.08.03.011	-	-	Not Available
Haemorrhage	24.07.01.002	-	-	Not Available
Varices oesophageal	09.01.06.009; 07.15.05.001; 24.10.02.004	0.000224%		Not Available
Fluid intake reduced	14.05.10.001	0.000548%		Not Available
Pulmonary mass	22.02.07.004	-	-	Not Available
Cutaneous lupus erythematosus	23.03.02.008; 15.06.02.007; 10.04.03.007	0.000112%		Not Available
Pneumatosis intestinalis	07.11.01.043	0.000504%		Not Available
Temperature intolerance	08.01.09.022	0.001556%		Not Available
Rectal tenesmus	15.05.03.011; 07.03.03.001	0.000504%		Not Available
Hypoaesthesia oral	07.05.05.003; 17.02.06.021	-	-	Not Available
Paraesthesia oral	17.02.06.008; 07.05.05.035	-	-	Not Available
Breast cancer female	21.05.01.011; 16.10.01.004	0.000795%		Not Available
Toxic skin eruption	12.03.01.073; 23.03.05.003; 10.01.01.008	0.000504%		Not Available
Cancer pain	16.32.03.004	0.000302%		Not Available
Post procedural complication	12.02.05.018	-	-	Not Available
Pulseless electrical activity	02.03.04.020	0.000280%		Not Available
Cystoid macular oedema	12.02.02.005; 06.04.06.010	0.000112%		Not Available
Nail pigmentation	23.02.05.007	0.000381%		Not Available
Oral toxicity	12.03.01.051; 07.05.01.012	0.000168%		Not Available
Skin oedema	23.06.04.001	0.000112%		Not Available
Disturbance in sexual arousal	19.08.04.003	-	-	Not Available
Haemobilia	24.07.01.049; 09.01.08.009	0.000112%		Not Available
Bicytopenia	01.03.03.010	0.000168%		Not Available

The 23th Page First Pre 23 24 25 26 27 Next Last Total 31 Pages